ClinicalTrials.Veeva

Menu

Qualitative Exploratory Study Among Reunionese Women and Their Partners Who Have a Child With Trisomy 21 (QUALI-21)

C

Centre Hospitalier Universitaire de la Réunion

Status

Enrolling

Conditions

Down Syndrome

Treatments

Behavioral: Interview

Study type

Observational

Funder types

Other

Identifiers

NCT04811534
2021/CHU/06

Details and patient eligibility

About

According to data from French congenital malformation registries, the prevalence of Down Syndrome (DS) in 2017 (live births and medical termination of pregnancy (MToP)) in Reunion Island was the lowest in France (23.04 per 10,000 births), notably in relation to a young maternal age. However, if we look at live births, Reunion Island has the highest prevalence of DS in France (12.24 vs. 5.81 per 10,000 births), despite a well organized prenatal diagnosis (PND). In fact, the use of MToP in this context is the lowest in France (10.8 vs 26.3 per 10 000 births).

Local specificities may have an impact on the choice of patients to undergo or not undergo a MToP in the context of PND of DS and explain why the rate of recourse to MToP is the lowest in France. To date, no qualitative study exploring the reasons why women and their partners do not undergo a MToP in the context of DS has been conducted in Reunion Island.

Thus, the main hypothesis is that the low recourse to MToP following PND of DS in Reunion Island could be explained by the beliefs, values or choices of Reunion Island women and their partners during pregnancy in relation to a specific family, socio-cultural and economic context.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Parents:

  • of a child born alive with Down Syndrome as of January 1, 2019 and registered within REMACOR
  • living on the island of Reunion at the time of birth
  • having a good understanding of French and/or Creole
  • having given their written consent to the study

Exclusion criteria

Parents:

  • with normal/negative prenatal screening (False positive)
  • minors at the time of inclusion
  • under guardianship or legal protection
  • with a pathology preventing the interviews from taking place

Trial contacts and locations

2

Loading...

Central trial contact

Hanitra RANDRIANAIVO

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems